3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
195
Gastrointestinal
7
Breast
5
Thoracic
4
Gynecologic
2
Dermatologic
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Classical hematology
1
Conditions
Prostatic Neoplasms
1
Liposarcoma
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Gemcitabine
4
pembrolizumab
3
Docetaxel
3
Cryosurgery
3
Biopsy
3
eribulin
2
durvalumab
2
balstilimab
2
atezolizumab
2
aflibercept
2
Zoledronic Acid
2
Trastuzumab
2
Taxes
2
Specimen Handling
2
Radiotherapy
2
Radiosurgery
2
Radiation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Irinotecan
2
Gene Expression Profiling
2
Fulvestrant
2
Cisplatin
2
Blood Specimen Collection
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
trifluridine tipiracil drug combination
1
tremelimumab
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
enzalutamide
×
Sarcoma
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled